Trading in EQL Pharma’s shares on Nasdaq Stockholm commences today

EQL Pharma AB ("EQL Pharma" or the "Company") announced on 12 June 2024 that Nasdaq Stockholm’s listing committee has approved that the Company’s shares are admitted to trading on Nasdaq Stockholm Main Market and published a prospectus with regards to the list change on 28 June 2024. Today, on 4 July 2024, the trading in the Company’s share on Nasdaq Stockholm commences.

CEO Axel Schörling comments: “The listing on Nasdaq Main Market gives us a quality stamp and is a natural step in EQL Pharma’s growth story. Our current annual revenue growth rate is around 40%, and we aim to continue to be a fast-growing company for many years to come. Through the Nasdaq listing, we also gain access to international capital markets and institutional investors can become shareholders of EQL to a greater extent than before.”

EQL Pharma’s share will be traded in the Small Cap segment and will retain both its ticker (EQL) and ISIN code (SE0005497732). In connection with the list change, there will be no offering or issue of new shares and shareholders of EQL Pharma will not need to take any actions.

The Company has, in connection with the list change, prepared a prospectus, which is available on the Company's website, www.eqlpharma.com.

Advisors

Setterwalls Advokatbyrå AB is acting as legal advisor to EQL Pharma in connection with the listing.

For more information contact:

Axel Schörling,

CEO & President EQL Pharma AB (publ)
Phone: +46 (0) 76 317 90 60
E-mail: axel.schorling@eqlpharma.com
Web: www.eqlpharma.com

EQL Pharma AB (publ) in short

EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has more than 40 niche generics (i.e., generics with limited competition apart from the original drug) launched in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2024 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, in the Nordics and selected European markets. EQL Pharma AB has its operations in Lund and is listed on Nasdaq Stockholm. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.